WiCell selects Agilent SurePrint G3 Human Genome CGH+SNP Microarray

WiCell, a company engaged in the cytogenetic testing of mouse and human embryonic stem cells and induced pluripotent stem cells, is offering comparative genomic hybridization plus single nucleotide polymorphism microarray analysis using Agilent Technologies Inc.'s SurePrint G3 Human Genome CGH+SNP Microarray.

The CGH+SNP Microarray detects copy number changes by both SNP and CGH, and simultaneously delivers copy-neutral change information such as loss or absence of heterozygosity.

The assay maintains the high-resolution quality achieved with CGH-only microarrays, using probes that have been carefully optimized and validated for maximal sensitivity and specificity, Agilent said.

"WiCell's considerable experience and know-how in cytogenetic analysis and their large CGH dataset for embryonic and induced pluripotent stem cells, partners well with Agilent's technology to enable robust detection capabilities vital for research and commercial development," said Kathleen Shelton, senior director of genomics marketing at Agilent.